Evidence map›Paper›PMID 27039911›Full record

ArticleZeitschrift fur Rheumatologie2014

[Recommendations on the use of rituximab for ANCA-associated vasculitis].

A M Gause, A Rubbert-Roth, Kommission für Pharmakotherapie

Abstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

A M GauseRheumapraxis Bad Bramstedt, Sommerland 55, 24576, Bad Bramstedt, Deutschland. amgause@rheuma-bb.de.
A Rubbert-RothKlinik I für Innere Medizin, Uniklinik Köln, Köln, Deutschland.
Kommission für Pharmakotherapie
Centrum für Integrierte Onkologie · DEHNO Bad Bramstedt · DEKlinik und Poliklinik für Psychosomatik und Psychotherapie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab (Rtx) has been approved in Germany since April 2013 for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This therapy can be used in severe manifestations of these diseases and in relapses. It is administered as infusions of 375 mg rituximab per m(2) every 4 weeks after high dose intravenous prednisolone for 3 days and continued parallel to concomitant oral prednisolone therapy. Recommendations for the indications and use for antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) are described in addition to previous publications on recommendations for rheumatoid arthritis.

Indexed as

Practice Guidelines as TopicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntirheumatic AgentsArthritis, RheumatoidDose-Response Relationship, DrugDrug Administration ScheduleEvidence-Based MedicineGermanyHumansImmunologic FactorsRituximabTreatment OutcomeAntirheumatic AgentsImmunologic FactorsRituximabCyclophosphamideGranulomatosis with polyangiitisMicroscopic polyangiitisRemission inductionSide effects

Identifiers

PMID27039911
OpenAlexW162374948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.